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Abstract 
Purpose: To investigate the impact of areas of decreased fundus autofluorescence (AF) on visual 
acuity (VA) in molecularly confirmed Stargardt disease (STGD1) with recent symptom onset, 
and investigate the association between these structural and functional measures over time. 
Design: Prospective international, multi-center, observational study of Stargardt disease. 
Participants: 64 patients (124 eyes) aged ≥six years at first study visit, with onset of symptoms 
≤2 years before the first visit.  
Methods:  AF images were graded for the presence and areas of definitely decreased AF 
(DDAF), questionably decreased AF (QDAF), and total decreased AF (DAF). First visit images 
were also graded for presence of these lesions and for the presence of increased AF in the fovea. 
VA was measured as best corrected or presenting acuity and converted to LogMAR. Cross-
sectional associations were measured using linear models with Generalized Estimating 
Equations. Longitudinal linear mixed effects models were used to estimate yearly progression 
rates of VA and AF lesion areas.  
Main Outcome Measures: Rate of change in VA and rate of change of decreased AF area.  
Results: In cross-sectional analyses at baseline, VA was not significantly associated with area of 
DDAF (p=0.86), or QDAF (p=0.11), but was significantly associated with lesion involvement in 
the fovea (p<.001). The VA change rate was 0.054 LogMAR/year (p<.001), and depended on 
initial level of VA (faster loss was observed in those with 20/30-20/70 at first visit, 0.114 
LogMAR/year, 95% CI=.090-.138). Growth of DDAF depended on the size of the lesion at first 
visit, with larger DDAF having faster growth. Regression of QDAF area over time was 
associated with significantly larger growth in DDAF (p<.001) suggesting that QDAF areas may 
lose further AF signal over time. The increase in area of DDAF, or total decreased AF, was not 
associated with change in VA (p=0.62, and p=0.27, respectively). 
Conclusions: In recent onset STGD1, the rate of VA loss was not significantly associated with 
the rate of increase in area of DDAF, QDAF, or DAF. For DDAF, the growth rate depended on 
the initial size of the lesion, a finding which will be helpful in stratifying these patients for 
intervention.   
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Introduction 
Autosomal recessive Stargardt macular dystrophy (STGD1), caused by disease-causing sequence 
variants in the ABCA4 gene, is the most common form of juvenile macular degeneration1,2. The 
mutation causes degeneration of the macular photoreceptors and the retinal pigment epithelium 
(RPE) initially. The natural history of STGD1, and determining the rate of progression using a 
variety of assessments, is of intense interest with the prospect of several clinical trials of new 
treatment options3-5. Measures of progression can include structural measures such as 
abnormalities in retinal layers on optical coherence tomography, or primarily RPE abnormalities 
as demonstrated on fundus autofluorescence (AF) imaging; and functional measures such as 
visual acuity, or testing specific points of retinal function using microperimetry6. In this study, 
we determine the association of visual acuity (VA) with measures of retinal loss as determined 
by AF.     
 
Data suggest that the progression of STGD1 is dependent on several factors, which may include 
the prior duration of disease symptoms at the point at which progression is to be measured7 and 
baseline parameters such as the RPE lesion area measured by AF8.  Duration may thereby be a 
significant confounding factor in studying the natural history, or indeed confound the association 
between structural and functional measures. To mitigate this effect, we sought to evaluate the 
association of VA and AF in cases of recent onset Stargardt disease. 
 
The ProgStar (Progression of atrophy secondary to Stargardt disease) study, the largest 
prospective natural history study of STGD1 to date, also includes patients with recent symptom 
onset, herein defined as less than two years. By assessing the loss of VA and changes in AF, and 
evaluating the association of VA with AF in this cohort, we aimed to better understand disease 
progression at the earliest stages when patients are likely to first present.   
 
Methods 
 
ProgStar is a natural history study of cases of STGD1, enrolled from 9 sites internationally. A 
detailed description of the study and the total population has been previously published6. In 
summary, there are two components of ProgStar, a retrospective chart review study of eligible 
patients, and a prospective cohort of patients who are currently being followed over time. The 
retrospective eligibility criteria were as follows: 1) patients (aged ≥ 6 years) with ≥2 pathogenic 
mutations in the ABCA4 gene or 1 pathogenic mutation with a typical STGD1 phenotype; 2) In 
the opinion of the clinical investigator, there was a well-defined atrophic lesion at the most 
recent visit of at least 300 µm in diameter; the total area of all lesions had to be ≤ 12 mm2. The 
presence of an atrophic lesion at the first retrospective visit was not required. The criteria were 
slightly different for the prospective study, in that eligible eyes had to have at least one well-
demarcated area of atrophy as visualized by AF with a minimum diameter of 300 µm, and all 
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lesions together had to add to less than or equal to 12 mm2; best-corrected VA had to be 20 
ETDRS letters (20/400 Snellen equivalent) or better.  
 
In ProgStar overall, 251 participants were enrolled in the retrospective study and 259 participants 
in the prospective study. For this study, we defined “recent onset” cases as the subset who self-
reported onset of symptoms within the previous two years prior to their first ProgStar visit. To be 
eligible for these analyses, patients also had to have both VA data and a gradable AF image at 
the first visit.  In the retrospective study, there were 36 recent onset patients who met such study 
criteria; contributing 69 eyes to the analyses. From the prospective study, 28 recent onset patients 
met study criteria, contributing 55 eyes to the analyses. Among the 124 study eyes, 118 had at 
least two visits with both AF and VA data which could be used for the longitudinal analyses   
 
Ethics committee approval was provided by all participating centers’ Institutional Review 
Boards and the Human Research Protection Office of the U.S. Army Medical Research & 
Materiel Command. The studies have been registered at www.clinicaltrials.gov (Identifier 
NCT01977846). All patients gave informed consent prior to enrollment in the study for the 
prospective component, and for the retrospective component where the ethical boards required 
consent.     
 
The chart abstraction of reported best corrected or presenting acuity was converted to LogMAR 
for the eyes from the retrospective study patients. For prospective study patients, best corrected 
ETDRS VA was measured during each study visit and converted to LogMAR. Chart review also 
recorded clinical exam results such as presence of RPE atrophy, or presence of flecks inside and 
outside the arcades  
 
AF images were obtained and graded as previously described6. In brief, AF images were eligible 
if obtained with a Heidelberg Engineering® (Heidelberg, Germany) device such as Heidelberg 
Retina Angiograph 2TM (HRA2) or Heidelberg SpectralisTM (excitation light 488 nm, barrier 
filter 500 nm).  These images were submitted to the Doheny Imaging Retina Center for grading. 
Using a standardized grading scheme as previously described6,9, the lesion areas were graded for 
definitely decreased AF (DDAF) and questionably decreased AF (QDAF). The total area of 
decreased AF (DAF) was then calculated as the sum of DDAF and QDAF. Images were also 
graded for the presence of a heterogeneous or homogeneous background. AF background 
uniformity was graded based on a previously published grading scheme: a homogeneous 
background (outside of lesion area) was defined as an even distribution of background 
autofluorescence; a heterogeneous background was defined as widespread small foci of 
increased or reduced autofluorescence8. The area of the respective lesions was semi-
automatically evaluated using the RegionFinder module of the Heidelberg EyeExplorerTM 
(Heidelberg Engineering©, Heidelberg, Germany) with standard grading conventions10. Two 
certified graders independently reviewed the AF images. Adjudication processes were applied in 
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cases of discordant gradings. If consensus could not be reached between two adjudicating 
graders, the final assessment was determined by a senior investigator. In addition, the baseline 
images were graded independently for the presence of a lesion, and type of lesion (DDAF, 
QDAF, or increased AF) in the foveal center point (Figure 1). Adjudication by a senior grader 
was obtained in cases of discordant gradings. 
 
We collected age at enrollment, gender, race, and duration of symptoms at the first visit either 
from the medical record or by direct interview.  
 
Patient demographic, and eye-level clinical and AF characteristics at the first visit were 
summarized. For VA specifically, baseline median and interquartile range was presented. 
Referencing the World Health Organization's International Classification of Diseases, 10th 
revision11, VA was also categorized and tabulated as ≥20/30 (LogMAR≤ 0.18) (i.e. no/minimal 
visual impairment [VI]), <20/30 to 20/70 (LogMAR 0.18-0.54) (i.e. mild VI), <20/70 to 20/200 
(LogMAR 0.54-1.0) (i.e. moderate VI), and <20/200 (LogMAR 1.0-1.3) (i.e. severe VI or 
blindness). For the cross sectional associations between VA and AF lesion areas or other 
variables, linear models with Generalized Estimating Equations (GEE) were used.  
 
Linear mixed effects models (LMM) were used on the longitudinal data to estimate the yearly 
progression rate of VA and lesion areas: the mean of VA or lesion areas was modeled as a linear 
function of time since baseline visit, with the intercept and slope parameters assumed to be 
normally distributed random effects. The LMM essentially estimated an average linear trend 
from all individuals, while the random effects allowed random variation of each individual’s 
trajectory from the average trend. A compound symmetry covariance matrix was adopted for the 
measurement errors of the outcome variable. The model thus accounted for correlation between 
repeated measurements of the same eye and correlation between eyes of the same participant. 
The assumption of a linear trend was examined by graphical inspection. To further identify 
baseline variables (e.g. initial VA level or lesion size) associated with VA or AF lesion change 
rate, LMMs were used by including each variable and its interaction with time. Testing the 
coefficient of the interaction term infers whether the variable was associated with VA or AF 
lesion change rate. Additionally, use of the square root of AF lesion sizes was considered in the 
modeling. However, due to the difficulty in interpretation when modeling it with the outcome of 
VA, results from the original linear models were reported which showed reasonable model fit.  
 
For the analysis estimating the associations between growth in AF lesion areas and change in VA 
during follow-up, the changes from the first visit to the last visit were first calculated for VA and 
lesion areas respectively, and linear models with GEE were then used to estimate the VA change 
associated with DDAF and total DAF growth. Additionally, a sub-analysis using linear models 
with GEE was conducted to examine whether the decrease in QDAF lesion area was associated 
with an increase in DDAF area, using eyes that showed decreased QDAF area by the last visit.  
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All analyses were conducted in SAS 9.3, and two-sided p-values from Wald-tests were reported. 
All statistical tests used significance level alpha of 0.05.  For the cross-sectional analysis using 
GEE models, model fit was assessed using aggregated residuals, and for the longitudinal analysis 
using LMMs, model fit was assessed using plots of scaled residuals12, both of which was deemed 
reasonable. 
 
Results  
 
The sample for the cross-sectional analyses (N=64, 124 eyes) was 59% female, with a median 
age of 22.5 years (Table 1). The median VA was 0.68 (Interquartile range (IQR)=0.22-0.88) with 
45% of the eyes having moderate impairment (VA worse than 20/70, up to 20/200) and 14.5% 
having severe impairment (VA worse than 20/200). In these recent onset cases, DDAF was 
present in 28.2% of eyes (N=35 eyes), and the mean area in these eyes was 1.76 mm2. A total of 
107 eyes (86.3%) had QDAF, and the mean area was 1.17 mm2 (Table 1).  
 
Cross-sectional analysis 
The mean acuity of those eyes with DDAF was 0.60 at baseline (20/80 Snellen equivalent), and 
those with QDAF was 0.61 LogMAR. There were too few eyes with no lesion at baseline to 
reliably determine VA. Older age of onset was associated with better VA, and RPE atrophy 
found on clinical exam was associated with worse VA at first visit. Presence of an AF lesion in 
the fovea was associated with worse VA (Table 2): compared with no lesion in the fovea, the 
presence of DDAF in the fovea was associated with a worse VA of 0.52 LogMAR (~5 lines), 
and the presence of QDAF in the fovea was associated with a worse VA of 0.31 (~3 lines). 
Increased AF in the fovea was associated with a worse VA of 0.35 (~3.5 lines), but the 
association was not statistically significant. These associations can be seen in the boxplots in 
Figure 2 showing the distributions of VA by AF lesion type in the fovea. However, larger areas 
of DDAF, QDAF and total DAF were not significantly associated with worse VA (Table 3).  
 
Longitudinal analysis: AF area change over follow-up 
The median follow-up time for the longitudinal component of the analyses was 1 year, with an 
IQR of 1-3.2 years. The rate of change over time in area of DAF depended both on the lesion 
type and the initial size. For DDAF, the average rate of area growth was 0.39mm2/year, (95% 
CI=.28-.51, p<.001) (Figure 3A), but the growth rate depended on the initial size of the lesion at 
first visit: for each 1 mm2 larger in lesion size at the first visit, the rate of growth was 0.37 mm2 
larger per year (p<.001). For QDAF, the average increase was 0.11 mm2 /year (95% CI=.05-0.16 
mm2) (p<.001) (Figure 3B). Interestingly, over time in 32 eyes, the QDAF lesion decreased. For 
those eyes that lost QDAF, we hypothesized that there would be a corresponding increase in 
DDAF. Analysis showed the association was significant, that for every 1 mm2 decrease in 
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QDAF, there was a corresponding growth in DDAF area of 0.45 mm2 (95% CI=0.29-0.61 mm2), 
p=<.001.  
 
Longitudinal analysis: VA change over follow-up 
The overall rate of change in VA was 0.054 LogMAR/year (p=<.001), equivalent to about ½ of a 
Snellen line per year, but the rate of change depended on the starting level of VA. (Figure 4a-d). 
The faster rate of VA loss occurred among eyes with no or mild visual impairment at first visit, 
slowed for eyes with moderate visual impairment, and actually improved for those whose 
starting vision was worse than 20/200.  
 
We incorporated VA at first visit in models examining the impact of other predictors on rate of 
change in VA over time.  Table 4 shows the baseline characteristics that were examined for an 
association with greater or lesser rate of change in VA. Older age at baseline (or older age of 
symptom onset) was significantly associated with slower VA change after adjusting for baseline 
VA level. Baseline size of QDAF was not associated with VA change rate. The baseline size of 
the area of DDAF and total DAF was associated with the rate of change VA in unadjusted 
analysis, but such association was not significant after adjusting for baseline VA level.  Eyes 
without any lesion in the fovea at baseline had a mean VA loss rate of 0.066 LogMAR/year; eyes 
with QDAF lesion in the fovea had a VA loss rate of .031 LogMAR/year; eyes with DDAF in 
the fovea had a non-significant loss rate of .004 LogMAR /year; and eyes with increased AF in 
the fovea also had a non-significant loss rate of.031 LogMAR/year. However, once adjusted for 
baseline VA status, the presence of DDAF and QDAF, compared to having no lesion in the 
fovea, was significantly associated with a greater rate of loss of VA, the difference in rate of loss 
of VA being 0.102 and .047 LogMAR/year respectively.  Clinically observed flecks inside the 
arcades at baseline was not associated with VA change. Clinically observed flecks outside the 
arcades, or having a heterogeneous background on AF image had slower rate of change in VA 
than those with a homogeneous background or no flecks outside the arcades.       
 
Longitudinal analysis: AF change vs. VA change over follow-up  
We hypothesized that a faster decline in VA would be predicted by a faster growth in DDAF or 
DAF area over the follow up period. However, we did not find that the change in VA over the 
follow-up period was significantly associated with the growth in area of DDAF, or DAF, alone 
or adjusted for the baseline level of VA (Table 5 and Figure 5). (Figures 6 and 7 in supplemental 
materials show the overall change in DAF area, and overall change in VA. Available at 
aaojournal.org)  
 
Discussion  
We presented data of a cohort of STGD1 patients derived from ProgStar with recent onset of 
symptoms, and assessed the association of vision, as estimated by VA, and presence of RPE 
 9 
lesions, as demonstrated by AF. Assessment in such a cohort minimized any potential 
confounding due to differing duration of symptoms in the patients.  
 
Of note, even in this group of patients with onset of symptoms within the last two years, with a 
median age of just 22.5 years, more than half the sample of eyes had acuity worse than 20/70 at 
baseline and 94% had DAF in their images already. However, almost ¾ of the eyes were graded 
as not having a heterogeneous background in their images, and close to 60% did not have flecks 
outside the arcades through clinical observation. The clinical picture of these recent onset cases 
is one of a sizeable number with poor vision and DAF in the images, but not disseminated 
disease in terms of heterogeneous background or flecks outside the arcades. This baseline is 
critical to understanding the risk of losing vision in patients reporting recent onset of symptoms.      
 
We observed a faster rate of VA loss associated with a homogeneous background at baseline, 
compared to a heterogeneous background. The rate of VA loss was low for those with 
heterogeneous backgrounds (.017 LogMAR/year), but in general, less than ¼ of eyes in these 
new onset presented with heterogeneous background. We also found faster progression of VA 
associated with younger age (i.e. with earlier onset of symptoms). This finding conforms to other 
studies and to our analysis with the overall ProgStar retrospective cohort 13,14.      
 
At baseline, ~20% eyes had no lesion in the fovea. A similar proportion was reported previously 
for STDG1 patients with foveal sparing phenotype15,16. In our cohort, however, eyes with no 
foveal lesion could include both eyes with foveal sparing (AF lesion encircling the fovea ≥ 180°) 
and eyes with extrafoveal (but not fovea encircling) lesion. We found cross sectional associations 
between the presence of DAF lesions (DDAF or QDAF) in the fovea, and worse vision at 
baseline. The presence of increased AF in the fovea was also associated with worse vision with a 
point estimate similar to QDAF, but was not statistically significant likely due to small numbers 
with this lesion type in the fovea.  Longitudinally, adjusted for baseline acuity, the rate of loss of 
acuity was greater in eyes with QDAF and DDAF in the fovea at baseline compared to eyes that 
did not have these lesions. This finding is logical, as high visual acuity depends on anatomical 
integrity of the foveal center and acuity is worse if measured using an eccentric locus 17,18. 
Others have also found that loss of VA over time is slower in those with no lesion in the fovea at 
the outset19. It is known that foveal sparing phenotype is on the milder end of the spectrum of 
STGD1 and that VA of STGD1 patients with foveal sparing can be well-maintained till later 
stage16,20,21. In our analysis, however, the rate of VA change in eyes with no foveal lesion at 
baseline was faster (not statistically significant) than eyes with increased AF at baseline. This 
faster rate in eyes with no foveal lesion could be driven by those eyes with non fovea encircling 
lesion. We are limited to test this given that our grading did not differentiate between eyes with 
foveal sparing and eyes with non fovea encircling lesion.   
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Unlike to previously reported, 22we did not find significant associations between AF lesion 
growth and VA decline. This finding is supported by: first, we found no statistically (or 
clinically) significant association cross-sectionally of worse vision with the larger area of DDAF, 
QDAF, or total DAF lesion at baseline; second, longitudinally, with larger area of QDAF or 
DDAF at baseline, we found a slower rate of change in visual acuity over time, but once adjusted 
for baseline acuity, there was no significant difference in the rate of change in acuity with larger 
size of either lesion; third, in modeling the area of growth in DDAF or total DAF over time, we 
found no significant association of larger lesion growth with greater change in VA during the 
time. These all suggest that faster lesion growth may not be associated with faster rate of 
worsening vision. We were hampered in further characterizing these associations by the absence 
of data on the location of the DAF lesion at baseline (except in the fovea), and the direction of 
growth, especially into the fovea or into an eccentric locus. Thus, if the lesion area is large or 
growing, but remains sparing the fovea or the eccentric locus, there may be no or modest change 
in vision. Alternatively, small lesions that are in the foveal center will correlate with poor vision 
at the outset, and further growth may not greatly impact the already poor vision. Another 
explanation may be that the relatively small rate of change in QDAF (0.11 mm2/year) and DDAF 
(on average 0.67mm2) may not be enough to hasten visual acuity loss in these new onset cases. 
Others have found a lack of association of acuity with growth in DAF lesions as well23. Finally, 
our follow-up period was on average one year, with an interquartile range of 3.2 years; this 
interval may not have been sufficient to observe an impact of growth of DAF on change in visual 
acuity. If so, then the functional consequences of growth in DAF in a relatively short period is 
very low.  
 
For recent onset cases, the rate of increase in area of DAF depended on whether it was DDAF or 
QDAF, and for DDAF, the initial size of the lesion. As expected, the initial lesion size was 
smaller than the full patient population enrolled in ProgStar6. Our rate of growth for lesions of 
that size is consistent with the rate in other studies, where the initial lesion size was not reported 
as a factor for progression8,23,24. For QDAF, the overall growth rate for the recent onset cases was 
0.11 mm2/year, but decrease on QDAF area was also observed in 32 eyes, with associated 
increase in DDAF over the same time. This may reflect that QDAF converts to new areas of 
DDAF. This dynamic process is also supported by the fact that in our recent onset cases, at first 
visit most of the DAF was taken up with eyes that had QDAF (occurring in 107 of the 117 eyes 
with DAF).  
 
Longitudinally, we expected an association of a faster rate of growth of the area of DAF with a 
faster loss of VA, but this was not the case. The point estimates for the association were close to 
zero and not statistically significant. Several issues may affect this lack of association. Most 
importantly, it is likely critical to not only chart the growth in area, but the location of growth 
and whether the growth affected the foveal center or the preferred retinal locus (PRL). We would 
expect the association should be observed for those cases. Another issue is the possible 
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improvement in vision over time, which as discussed above, could reflect better adjustment to a 
PRL, even in the face of lesion growth as long as the growth is not in the PRL. Others have also 
found that acuity is not well associated with DAF growth over time, although lesion sizes were 
not reported in that study23. A third issue is, as mentioned before, growth of DAF in the 
relatively short duration of follow-up for these recent onset cases may not be large enough to 
significantly worsen VA.  
 
In recent onset cases, the rate of change in vision depended on vision at first visit, with worse 
rate of loss in those starting with mild or no vision impairment. The rates are very similar to 
those observed in the overall ProgStar retrospective cohort, although those with much longer 
duration of symptoms  presented with worse vision at first visit and tended to have a slower rate 
of change14. In the few recent onset patients who presented with very poor vision (VA>20/200), 
there was actual improvement in visual acuity of 0.04 Log MAR/year. This same trend was 
found in the overall ProgStar retrospective cohort, where the improvement in VA for those with 
poor VA at first visit was at a rate of 0.05 logMAR/year14. The improvement for this group is 
very modest, less than half a line. It might reflect regression to the mean, where patients with 
poor vision tested poorly at baseline, and tested slightly better at subsequent visits reflecting 
normal variation. Improvement may also reflect adjustment to change in PRL25. This latter 
explanation may be especially valid in the case of recent onset cases, whose onset was sudden 
with dramatic loss of vision at early visits, with adjustment over time.  We do not have 
microperimetry on the retrospective ProgStar patients to determine if eccentric fixation at first 
visit was present.  
 
In summary, our study of patients with recent onset Stargardt disease type 1 has found overall a 
small rate of VA loss per year, dependent on the level of VA at first visit. The worse VA at first 
visit was associated with presence of QDAF and DDAF in the fovea, but not the size of DAF 
lesions. Loss of VA over time was slower in those with larger DDAF or QDAF lesions, but not 
significantly slower once adjusted for baseline acuity levels. However, rate of loss of acuity was 
significantly worse with DAF in the fovea at baseline compared to no foveal lesion. The growth 
in DAF, and DDAF was not found to be associated with change in VA, suggesting that the 
location of lesion growth may be more important in determining the consequences for acuity 
than the physical AF lesion growth itself in patients with recent symptom onset.  
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Figure legends: 
Figure 1. Autofluorescence image showing different lesions from 4 different eyes with Stargardt 
disease. Image A shows foveal sparing disease with multifocal extrafoveal lesions; the yellow, 
green, and white arrows show DDAF lesions, QDAF lesions, and normal foveal area, 
respectively. Image B shows well-demarcated QDAF lesion (orange arrow) involving the foveal 
center surrounded by an area of poorly-demarcated QDAF lesion (green arrow). Image C shows 
a large DDAF lesion (yellow arrow) involving the foveal center surrounded by an area of poorly-
demarcated QDAF lesion (green arrow). Image D shows hyper-autofluorescent area involving 
the foveal center (white arrow) surrounded by another area of QDAF (green arrow) with a ring of 
edge hyper-autofluorescence. 
 
Figure 2:  Boxplots showing the distributions of visual acuity (VA) at the first study visit (N=124 
eyes) by fundus autofluorescence (AF) lesion findings at the foveal center. In each boxplot, the 
lower and upper boundary of the box represents the first quartile (i.e. 25th percentile) and the 
third quartile (i.e. 75th percentile) of the data, respectively; the horizontal black line in the box is 
the median; the black diamond is the mean; the lower and upper whiskers are the lowest and 
highest values (Nobs: number of eyes (observation) in the group). 
 
Figure 3: Spaghetti plots showing the change over time in definitely decreased autofluorescence 
(DDAF) area and questionably decreased autofluorescence (QDAF) area (N=118 eyes) in recent 
onset Stargardt. Each line shows data from one eye.  
3A. Spaghetti plot for DDAF area change. 
3B. Spaghetti plot for QDAF area change. (N=32 eyes had decreased QDAF over the follow-up 
period.) 
 
 
Figure 4: Spaghetti plot showing visual acuity change from baseline VA level. Each line shows 
VA data of one eye over the follow-up period.  
       4A: The rate of change in Visual Acuity in eyes with no or mild visual impairment at first 
visit (i.e. VA was 20/30 or better)*  
4B: The rate of change in Visual Acuity in eyes with moderate visual impairment at first 
visit (VA was <20/30 to 20/70)* 
4C. The rate of change in Visual Acuity in eyes whose acuity at first visit was <20/70-
20/200* 
4D: The rate of change in Visual Acuity in eyes with visual acuity at first visit <20/200* 
 
Figure 5. Scatter plots of the area of growth of DDAF (panel A) and total decreased 
autofluorescence (DAF; panel B) vs. the change of VA between the first and last visits. 
 
 
